First Page | Document Content | |
---|---|---|
Date: 2017-10-03 19:39:49 | Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study – Study AchAdd to Reading ListSource URL: www.visterrainc.comDownload Document from Source WebsiteFile Size: 127,86 KBShare Document on Facebook |